Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of vibegron vs placebo and tolterodine in overactive bladder
2017-003293-14Phase 3Completed
- Sponsor
- Urovant Sciences
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vibegron in overactive bladder (OAB), sponsored by Urovant Sciences. Started Apr 2018; status: completed.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2017-003293-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003293-14.